Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jakub T. Kopycinski"'
Autor:
Sven Kratochvil, Paul F. McKay, Jakub T. Kopycinski, Cynthia Bishop, Peter John Hayes, Luke Muir, Christopher L. Pinder, Deniz Cizmeci, Deborah King, Yoann Aldon, Bruce D. Wines, P. Mark Hogarth, Amy W. Chung, Stephen J. Kent, Kathrin Held, Christof Geldmacher, Len Dally, Nelson S. Santos, Tom Cole, Jill Gilmour, Sarah Fidler, Robin J. Shattock
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
A key aspect to finding an efficacious human immunodeficiency virus (HIV) vaccine is the optimization of vaccine schedules that can mediate the efficient maturation of protective immune responses. In the present study, we investigated the effect of a
Externí odkaz:
https://doaj.org/article/4c3b30ccf3f844fdb4a1bdab3e84d4fd
Autor:
Sivasankaran Munusamy Ponnan, Sathyamurthy Pattabiram, Kannan Thiruvengadam, Rajat Goyal, Nikhil Singla, Joyeeta Mukherjee, Shweta Chatrath, Philip Bergin, Jakub T Kopycinski, Jill Gilmour, Sriram Kumar, Malathy Muthu, Sudha Subramaniam, Soumya Swaminathan, Srikanth Prasad Tripathy, Hanna Elizabeth Luke
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213911 (2019)
Effective vaccine design relies on accurate knowledge of protection against a pathogen, so as to be able to induce relevant and effective protective responses against it. An ideal Human Immunodeficiency virus (HIV) vaccine should induce humoral as we
Externí odkaz:
https://doaj.org/article/fbdda473e15f435db4263384c2bc3a72
Autor:
Sivasankaran Munusamy Ponnan, Soumya Swaminathan, Kannan Tiruvengadam, Vidyavijayan K K, Narayana Cheedarla, Manohar Nesakumar, Sujitha Kathirvel, Rajat Goyal, Nikhil Singla, Joyeeta Mukherjee, Philip Bergin, Jakub T Kopycinski, Jill Gilmour, Srikanth Prasad Tripathy, Hanna Elizabeth Luke
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0203037 (2018)
A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was conducted in India in 2009 to test a subtype C prophylactic vaccine in a prime-boost regimen comprising of a DNA prime (ADVAX) and MVA (TBC-M4) boost. The
Externí odkaz:
https://doaj.org/article/609929367d3044ee84fda31ecc615414
Autor:
Gaudensia Mutua, Bashir Farah, Robert Langat, Jackton Indangasi, Simon Ogola, Brian Onsembe, Jakub T Kopycinski, Peter Hayes, Nicola J Borthwick, Ambreen Ashraf, Len Dally, Burc Barin, Annika Tillander, Jill Gilmour, Jan De Bont, Alison Crook, Drew Hannaman, Josephine H Cox, Omu Anzala, Patricia E Fast, Marie Reilly, Kundai Chinyenze, Walter Jaoko, Tomáš Hanke
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
We are developing a pan-clade HIV-1 T-cell vaccine HIVconsv, which could complement Env vaccines for prophylaxis and be a key to HIV cure. Our strategy focuses vaccine-elicited effector T-cells on functionally and structurally conserved regions (not
Externí odkaz:
https://doaj.org/article/4f123ec4f6fe44898924201105e4aa3e
Autor:
Sandhya Vasan, Arlene Hurley, Sarah J Schlesinger, Drew Hannaman, David F Gardiner, Daniel P Dugin, Mar Boente-Carrera, Roselle Vittorino, Marina Caskey, Johanne Andersen, Yaoxing Huang, Josephine H Cox, Tony Tarragona-Fiol, Dilbinder K Gill, Hannah Cheeseman, Lorna Clark, Len Dally, Carol Smith, Claudia Schmidt, Harriet H Park, Jakub T Kopycinski, Jill Gilmour, Patricia Fast, Robert Bernard, David D Ho
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e19252 (2011)
DNA-based vaccines have been safe but weakly immunogenic in humans to date.We sought to determine the safety, tolerability, and immunogenicity of ADVAX, a multigenic HIV-1 DNA vaccine candidate, injected intramuscularly by in vivo electroporation (EP
Externí odkaz:
https://doaj.org/article/54e6c0214ce848db98e3291e78e074a0
Autor:
Sven Kratochvil, Paul F. McKay, Jakub T. Kopycinski, Cynthia Bishop, Peter John Hayes, Luke Muir, Christopher L. Pinder, Deniz Cizmeci, Deborah King, Yoann Aldon, Bruce D. Wines, P. Mark Hogarth, Amy W. Chung, Stephen J. Kent, Kathrin Held, Christof Geldmacher, Len Dally, Nelson S. Santos, Tom Cole, Jill Gilmour, Sarah Fidler, Robin J. Shattock
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Frontiers in Immunology
Frontiers in Immunology
A key aspect to finding an efficacious human immunodeficiency virus (HIV) vaccine is the optimization of vaccine schedules that can mediate the efficient maturation of protective immune responses. In the present study, we investigated the effect of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7102707be7c6dfff828c2262b9e4c317